Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil- based chemotherapy of patients with primary invasive breast cancer

Pharmacogenetics and Genomics

Volumn 17, Issue 7, 2007, Pages 529-538

  Jaremko, Malgorzata ^a,e   Justenhoven, Christina ^a   Schroth, Werner ^a   Abraham, Benny K ^a   Fritz, Peter ^a,b   Vollmert, Caren ^c   Illig, Thomas ^c   Simon, Wolfgang ^b   Schwab, Matthias ^a   Brauch, Hiltrud ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Anthracyclines; Breast cancer; Chemotherapy; Cyclophosphamide methotrexate 5 fluorouracil; DNA repair enzymes; Pharmacogenetics; XRCC1

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CELL CYCLE REGULATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICAL ANALYSIS; SURVIVAL; XRCC1 GENE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; HAPLOTYPES; HUMANS; METHOTREXATE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 34250213645     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32801233fc     Document Type: Article

References (63)

1. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6:133-146.
2. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352:930-942.
3. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339:974-984.
4. Calabresi P, Chabner BA. Chemotherapy of neoplastic dieseases. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, editors. The pharmacological basis of therapeutics. New York, St Louis, San Francisco, Auckland, Bogotá, Caracas, Lisbon, London, Madrid, Mexico City, Milan, Montreal, New Delhi, San Juan, Singapore, Sydney, Tokyo, Toronto: Mc-Graw-Hill; 1996. pp. 1225-1269.
5. Friedberg EC. DNA damage and repair. Nature 2003; 421:436-440.
6. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001; 291:1284-1289.
7. Ronen A, Glickman BW. Human DNA repair genes. Environ Mol Mutagen 2001; 37:241-283.
8. Mohrenweiser HW, Xi T, Vazquez-Matias J, Jones IM. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 2002; 11:1054-1064.
9. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002; 94:1091-1099.
10. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2005.
11. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006; 45:253-285.
12. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105:4752-4758.
13. Jin Y, Desta Z, Stearns V,Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97:30-39.
14. Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 2004; 4:143-153.
15. Thompson LH,West MG. XRCC1 keeps DNA from getting stranded. Mutat Res 2000; 459:1-18.
16. Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von FD, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005; 11:4802-4809.
17. Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003; 12:1168-1174.
18. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21:3075-3079.
19. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6:117-129.
20. Jaremko M, Justenhoven C, Abraham BK, Schroth W, Fritz P, Brod S, et al. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat 2005; 25:232-238.
21. Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, et al. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev 2004; 13:2059-2064.
22. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
23. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169.
24. Nash RA, Caldecott KW, Barnes DE, Lindahl T. XRCC1 protein interacts with one of two distinct forms of DNA ligase III. Biochemistry 1997; 36:5207-5211.
25. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 1996; 15:6662-6670.
26. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de MJ, de MG. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998; 18:3563-3571.
27. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J 1997; 11:68-76.
28. Callebaut I, Mornon JP. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett 1997; 400:25-30.
29. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998; 58:604-608.
30. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999; 59:2557-2561.
31. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000; 21:965-971.
32. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001; 22: 917-922.
33. Vodicka P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 2004; 25:757-763.
34. Ruzzo A, Graziano F, Kawakami K,Watanabe G, Santini D, Catalano V, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006; 24:1883-1891.
35. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006; 24:1720-1728.
36. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCCI and ERCC2 expression in malignant tissues from ovarian cancer patients. J Nat! Cancer Inst 1992; 84:1512-1517.
37. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, et al. A nucleotide polymorphism in ERCCI in human ovarian cancer cell lines and tumor tissues. Muta Res 1997; 382:13-20.
38. Xu Z, Chen ZP, Malapetsa A, aoui-Jamali M, Bergeron J, Monks A, et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002; 13:511-519.
39. Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, Grossman L, et al. Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001; 61:7430-7434.
40. Spitz MR,Wu X,Wang Y,Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61:1354-1357.
41. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000; 21:551-555.
42. Tang D, Cho S, Rundle A, Chen S, Phillips D, Zhou J, et al. Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res Treat 2002; 75:159-166.
43. Fan F, Liu C, Tavare S, Arnheim N. Polymorphisms in the human DNA repair gene XPF. Mutat Res 1999; 406:115-120.
44. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCCI and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004; 110:352-361.
45. Kumar R, Hoglund L, Zhao C, Forsti A, Snellman E, Hemminki K. Single nucleotide polymorphisms in the XPG gene: determination of role in DNA repair and breast cancer risk. IntJ Cancer 2003; 103:671-675.
46. Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 2001; 14:305-315.
47. Smith TR, Levine EA, Perrier ND, Miller MS, Freimanis RI, Lohman K, et al. DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prey 2003; 12:1200-1204.
48. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111:1843-1850.
49. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCAI in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96:1659-1668.
50. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63:6221-6228.
51. Han W, Kang D, Park IA, Kim SW, Bae JY, Chung KW, et al. Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. Clin Cancer Res 2004; 10:124-130.
52. Huuhtanen RL, Wiklund TA, Blomqvist CP, Bohling TO, Virolainen MJ, Tribukait B, et al. A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients. Br J Cancer 1999; 81:1017-1021.
53. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003; 3:617-633.
54. Bae DS, Cho SB, Kim YJ, Whang JD, Song SY, Park CS, et al. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 2001; 81:341-347.
55. Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, et al. Prognostic significance of CCND1 (cyclin Dl) overexpression in primary resected non- small-cell lung cancer. Br J Cancer 1996; 73:294-300.
56. Ikehara M, Oshita F, Ito H, Ohgane N, Suzuki R, Saito H, et al. Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung. Oncol Rep 2003; 10:137-139.
57. Pagano M, Theodoras AM, Tam SW, Draetta GE. Cyclin DI-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994; 8:1627-1639.
58. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-1677.
59. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11:1005-1011.
60. Zimmet JM, Ladd D, Jackson CW, Stenberg PE, Ravid K. A role for cyclin D3 in the endomitotic cell cycle. Mol Cell Biol 1997; 17:7248-7259.
61. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
62. Kastan MB, Onyekwere 0, Sidransky D, Vogeistein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304-6311.
63. Dumont P, Leu JI, Della PA, III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-365.